[1]Dernellis J, Panaret M. C-creative protein and paroxysmal atrial fibrillation:evidence of implication of an inflammatory process in paroxysmal atrial fibrillation[J]. Acta Cardiol, 2001,56(6):375
[2]Guo Y T, Gregory Y L, Apostolakis Set al. Inflammation in atrial fibrillation[J]. JACC, 2012,60(22):2263
[3]Madjid M, Ali M, Willerson J T. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature[J]. Tex Heart Inst J, 2010,37(1):25
[4]Bruins P, te Velthuis H, Yazdanbakhsh A P, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia[J]. Circulation, 1997,96(10):3542
[5]Engelmann M D, Svendsen J H. Inflammation in the Genesis and perpetuation of atrial fibrillation[J]. Eur Heart J, 2005,26(20):2083
[6]Hagiwara N. Inflammation and atrial fibrillation[J]. Circ J, 2010,74(2):246
[7]Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation[J].Heart Vessels,2005,20(2):45
[8]孙冰,刘和平,安佰富,等.心房颤动患者高敏C反应蛋白水平的变化及临床意义[J].中国老年学杂志, 2011,31(23):4685
[9]吴辉,程海旭,丁家望,等.心房颤动的炎症机制研究进展[J].国际心血管病杂志, 2013,40(4):196
[10]Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A(2) in atherosclerosis - Biology, epidemiology, and possible therapeutic target[J]. Arterioscler Thromb Vasc Biol, 2005,25(5):923
[11]张静,李学文.炎症因素及氧化应激与心房颤动心肌重构的相关性研究[J].中西医结合心脑血管病杂志, 2014,12(5):565
[12]Patel P, Dokainish H, Tsai P, et al. Update on the association of inflammation and atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2010,21(9):1064
[13]Rudolph V, Andrie R P, Rudolph T K, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation[J]. Nat Med, 2010,16(4):19
[14]Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation[J]. Cardiovasc Res, 2011,89(4):744
[15]Okumura Y, Watanabe I, Nakai T, et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence[J]. J Cardiovasc Electrophysiol, 2011,22(9):987
[16]Alegret J M, Aragonès G, Beltrán-Debón R, et al. The?relevance?of? the?association?between inflammation?and?atrial fibrillation[J]. Eur J Clin Invest, 2013,61 (10, Supplement):E314
[17]Cruhitzsch H, Menes A D. The role of artrial remodeling for ablation of artrial fibrillation[J]. Ann Thorac Surg, 2008,85(2):474
[18]Hagiwara N. Inflammation and atrial fibrillation[J]. Cite J, 2010,74(2):246
[19]Toutouzas K, Synetos A, Drakopoulou M, et al. The role of inflammation in atrial fibrillation: a myth or a fact[J]. Am J Med Sci, 2009,338(6):494
[20]Cianfrocca C, Loricchio M L, Pelliccia F, et al. C-reactive protein and left atrial appendage velocity are Independent determinants of the risk of thrombogenesis in patients with atrial fibrillation[J]. Int J Cardiol, 2010,142(1):22
[21]Lappeg?rd K T, Hovland A, Pop G A, et al. Atrial fibrillation: inflammation in disguise [J]. Scand J Immunol, 2013,78(2):112
[22]Fauchier L, Pierre B, de L A, et al. Anti-arrhythmic effect of statin therapy and atrial fibrillation a meta analysis of randomized controlled trials[J]. J Am Coll Cardiol, 2008,51(8):828
[1]王爱芬,崔利军,马向红.非瓣膜性心房颤动左心房/左心耳血栓形成的相关因素分析[J].天津医科大学学报,2015,21(02):130.
WANG Ai-fen,CUI Li-jun,MA Xiang-hong.Related factors of left atrial or left atrial appendage thrombus formation in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(03):130.
[2]陈延勋,李广平. 非瓣膜性心房颤动患者尿酸与CHADS2、CHA2DS2-VASc评分的关系[J].天津医科大学学报,2015,21(03):185.
CHEN Yan-xun,LI Guang-ping. Relationship between uric acid and CHADS2/CHA2DS2-VASc Score in patients with nonvalvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(03):185.
[3]付伟伟,李国东,王 喆.HDL-C与非瓣膜性心房颤动左心房/左心耳血栓形成的关系[J].天津医科大学学报,2015,21(06):498.
FU Wei-wei,LI Guo-dong,WANG Zhe.Relationship between high-density lipoprotein cholesterol and left atrial / left atrial appendage thrombus in non-valvular atrial fibrillation patients[J].Journal of Tianjin Medical University,2015,21(03):498.
[4]张彦月,林文华.vWF及血浆D-二聚体水平对非瓣膜性心房颤动患者血栓形成的诊断及临床预后价值[J].天津医科大学学报,2016,22(02):101.
ZHANG Yan-yue,LIN Wen-hua.Value of vWF and?D-dimer for thrombosis and prognosis in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(03):101.
[5]刘运龄,赵艳淑,刘恩照,等.不同类型心房颤动患者心脏结构及B型钠尿肽水平的变化[J].天津医科大学学报,2016,22(06):522.
LIU Yun-ling,ZHAO Yan-shu,LIU En-zhao,et al.Relationship between plasma leves B-type natriuretic peptide and cardiac structure in patients with different types of atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(03):522.
[6]张邦滢 综述,李广平 审校.新型抗心律失常药物在心房颤动中的应用[J].天津医科大学学报,2017,23(01):90.
[7]张凤环,上官文锋,王学文,等.血管紧张素-(1-7)对快速心房起搏犬心房重构及p38MAPK蛋白表达的影响[J].天津医科大学学报,2019,25(05):450.
ZHANG Feng-huan,SHANGGUAN Wen-feng,WANG Xue-wen,et al.Effect of angiotensin-(1-7) on atrial remodeling and p38MAPK expression in a canine model of rapid atrial pacing[J].Journal of Tianjin Medical University,2019,25(03):450.
[8]杜春蕾,郭 牧,张云强,等.尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究[J].天津医科大学学报,2019,25(05):471.
DU Chun-lei,GUO Mu,ZHANG Yun-qiang,et al.Comparison of nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients[J].Journal of Tianjin Medical University,2019,25(03):471.
[9]张茂芃,陈炳伟,卢成志,等.脉冲场消融治疗心房颤动的短期及长期安全性临床研究[J].天津医科大学学报,2023,29(06):636.
ZHANG Mao-peng,CHEN Bing-wei,LU Cheng-zhi,et al.The short-term and long-term safety clinical trial of pulse field ablation to treat atrial fibrillation[J].Journal of Tianjin Medical University,2023,29(03):636.
通信作者:徐延敏,E-mail:xuyanminphd@aliyun.com。